Literature DB >> 17600133

A network model to predict the risk of death in sickle cell disease.

Paola Sebastiani1, Vikki G Nolan, Clinton T Baldwin, Maria M Abad-Grau, Ling Wang, Adeboye H Adewoye, Lillian C McMahon, Lindsay A Farrer, James G Taylor, Gregory J Kato, Mark T Gladwin, Martin H Steinberg.   

Abstract

Modeling the complexity of sickle cell disease pathophysiology and severity is difficult. Using data from 3380 patients accounting for all common genotypes of sickle cell disease, Bayesian network modeling of 25 clinical events and laboratory tests was used to estimate sickle cell disease severity, which was represented as a score predicting the risk of death within 5 years. The reliability of the model was supported by analysis of 2 independent patient groups. In 1 group, the severity score was related to disease severity based on the opinion of expert clinicians. In the other group, the severity score was related to the presence and severity of pulmonary hypertension and the risk of death. Along with previously known risk factors for mortality, like renal insufficiency and leukocytosis, the network identified laboratory markers of the severity of hemolytic anemia and its associated clinical events as contributing risk factors. This model can be used to compute a personalized disease severity score allowing therapeutic decisions to be made according to the prognosis. The severity score could serve as an estimate of overall disease severity in genotype-phenotype association studies, and the model provides an additional method to study the complex pathophysiology of sickle cell disease.

Entities:  

Mesh:

Year:  2007        PMID: 17600133      PMCID: PMC1988954          DOI: 10.1182/blood-2007-04-084921

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Glasgow Outcome Scale: research scale or blunt instrument?

Authors:  A H Kaye; D Andrewes
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

2.  Physiologic, pathologic and therapeutic implications for hemoglobin interactions with nitric oxide.

Authors:  Rakesh P Patel; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2004-02-15       Impact factor: 7.376

Review 3.  Sickle-cell disease.

Authors:  Marie J Stuart; Ronald L Nagel
Journal:  Lancet       Date:  2004 Oct 9-15       Impact factor: 79.321

4.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

5.  Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia.

Authors:  Paola Sebastiani; Marco F Ramoni; Vikki Nolan; Clinton T Baldwin; Martin H Steinberg
Journal:  Nat Genet       Date:  2005-03-20       Impact factor: 38.330

6.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

7.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

8.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

Review 9.  The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.

Authors:  Robert P Hebbel; Raymond Osarogiagbon; Dhananjay Kaul
Journal:  Microcirculation       Date:  2004-03       Impact factor: 2.628

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  61 in total

1.  Pulmonary hypertension and NO in sickle cell.

Authors:  Mark T Gladwin; Robyn J Barst; Oswaldo L Castro; Victor R Gordeuk; Cheryl A Hillery; Gregory J Kato; Daniel B Kim-Shapiro; Roberto Machado; Claudia R Morris; Martin H Steinberg; Elliott P Vichinsky
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

2.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

Review 3.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 4.  Evolution and challenges in the design of computational systems for triage assistance.

Authors:  María M Abad-Grau; Jorge Ierache; Claudio Cervino; Paola Sebastiani
Journal:  J Biomed Inform       Date:  2008-02-05       Impact factor: 6.317

5.  Prediction of chronic obstructive pulmonary disease (COPD) in asthma patients using electronic medical records.

Authors:  Blanca E Himes; Yi Dai; Isaac S Kohane; Scott T Weiss; Marco F Ramoni
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

Review 6.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

7.  Association between renal function parameters, clinical severity score and mortality risk among adult Sudanese sickle anemia patients.

Authors:  Mohamed Ao Suliman; Alnazeer Ma Hassan; Lamis A Kaddam
Journal:  Am J Blood Res       Date:  2020-12-15

Review 8.  Genome-wide association studies and the genetic dissection of complex traits.

Authors:  Paola Sebastiani; Nadia Timofeev; Daniel A Dworkis; Thomas T Perls; Martin H Steinberg
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

9.  Erythrocytapheresis: Do Not Forget a Useful Therapy!

Authors:  Heidrun Ullrich; Roland Fischer; Regine Grosse; Uwe Kordes; Claudia Schubert; Bettina Altstadt; Georges Andreu
Journal:  Transfus Med Hemother       Date:  2008-01-15       Impact factor: 3.747

10.  Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia.

Authors:  Chun-Seok Cho; Gregory J Kato; Seung Ha Yang; Sung Won Bae; Jong Seo Lee; Mark T Gladwin; Sue Goo Rhee
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.